OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Market Valuation | Analysts set a $50 price target, reflecting confidence in OrthoPediatrics' unique market position and growth strategy in the specialized pediatric orthopedic secto |
Innovation Pipeline | Explore OrthoPediatrics' robust product development efforts, including delayed but promising launches of eLLi and VerteGlide, driving future growth potential |
Financial Health | Company projects positive cash flow by 2026, with EBITDA margins expected to reach 13-14% by 2027, supported by a recent $100 million financing deal |
Pediatric Orthopedics Pionee | OrthoPediatrics leads the underserved pediatric orthopedic market with impressive revenue growth and strategic expansion plans, targeting 71 markets by 2027 |
Metrics to compare | KIDS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKIDSPeersSector | |
---|---|---|---|---|
P/E Ratio | −20.6x | −11.1x | −0.6x | |
PEG Ratio | 0.88 | 0.38 | 0.00 | |
Price / Book | 1.6x | 1.8x | 2.6x | |
Price / LTM Sales | 3.1x | 1.8x | 3.1x | |
Upside (Analyst Target) | 66.8% | 39.6% | 48.7% | |
Fair Value Upside | Unlock | 20.7% | 7.7% | Unlock |